22.418 articles found

Therapeutic agents useful for treating pain

KYLE DONALD J, SUN QUN, TAFESSE LAYKEA, ZHOU XIAOMING.

· 2004-06-11

EPAS1 GENE TRANSFER TO IMPROVE CELL THERAPY

GUY Louis-Georges, FORTIN Anouk.

· 2004-06-04

Epas1 Gene Transfer to Improve Cell Therapy

LOUIS-GEORGES GUY, ANOUK FORTIN.

· 2004-06-04

EPAS1 GENE TRANSFER TO IMPROVE CELL THERAPY

GUY LOUIS-GEORGES, FORTIN ANOUK.

· 2004-06-04

A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.

El-Agnaf OM, Paleologou KE, Greer B, Abogrein AM, King JE, Salem SA, Fullwood NJ, Benson FE, Hewitt R, Ford KJ, Martin FL, Harriott P, Cookson MR, Allsop D.

FASEB J · 2004-06-04

DOI: 10.1096/fj.03-1346fjePMID: 15180968

RNA INTERFERENCE MEDIATED TREATMENT OF PARKINSON DISEASE USING SHORT INTERERING NUCLEIC ACID (siNA)

MCSWIGGEN James, HAEBERLI Peter, BEIGELMAN Leonid.

· 2004-06-03

RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)

MCSWIGGEN JAMES, HAEBERLI PETER, BEIGELMAN LEONID.

· 2004-06-03

Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off.

Rajput AH, Fenton ME, Di Paolo T, Sitte H, Pifl C, Hornykiewicz O.

Parkinsonism Relat Disord · 2004-06-01

DOI: 10.1016/j.parkreldis.2004.01.004PMID: 15120096

Therapeutic factors causing hallucination in Parkinson's disease patients, especially those given selegiline.

Kamakura K, Mochizuki H, Kaida K, Hirata A, Kanzaki M, Masaki T, Nakamura R, Motoyoshi K.

Parkinsonism Relat Disord · 2004-06-01

DOI: 10.1016/j.parkreldis.2004.01.006PMID: 15120098

Iris pigment epithelial cells: a possible cell source for the future treatment of neurodegenerative diseases.

Arnhold S, Semkova I, Andressen C, Lenartz D, Meissner G, Sturm V, Kochanek S, Addicks K, Schraermeyer U.

Exp Neurol · 2004-06-01

DOI: 10.1016/j.expneurol.2004.02.015PMID: 15144867

AMPA receptor potentiators for the treatment of CNS disorders.

O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES.

Curr Drug Targets CNS Neurol Disord · 2004-06-01

DOI: 10.2174/1568007043337508PMID: 15180479

Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.

Muhlack S, Woitalla D, Welnic J, Twiehaus S, Przuntek H, Müller T.

Neurosci Lett · 2004-06-01

DOI: 10.1016/j.neulet.2004.04.012PMID: 15182961